BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wagner AD, Syn NL, Moehler M, Grothe W, Yong WP, Tai BC, Ho J, Unverzagt S. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2017;8:CD004064. [PMID: 28850174 DOI: 10.1002/14651858.cd004064.pub4] [Cited by in Crossref: 77] [Cited by in F6Publishing: 166] [Article Influence: 15.4] [Reference Citation Analysis]
Number Citing Articles
1 Yoo JY, Cho HJ, Moon S, Choi J, Lee S, Ahn C, Yoo KY, Kim I, Ko KP, Lee JE, Park SK. Pickled Vegetable and Salted Fish Intake and the Risk of Gastric Cancer: Two Prospective Cohort Studies and a Meta-Analysis. Cancers (Basel) 2020;12:E996. [PMID: 32316595 DOI: 10.3390/cancers12040996] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
2 Zhang Z, Zhao W, Lin X, Gao J, Zhang Z, Shen L. Voltage-dependent calcium channel α2δ1 subunit is a specific candidate marker for identifying gastric cancer stem cells. Cancer Manag Res 2019;11:4707-18. [PMID: 31213895 DOI: 10.2147/CMAR.S199329] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
3 Chen W, Zhang K, Yang Y, Guo Z, Wang X, Teng B, Zhao Q, Huang C, Qiu Z. MEF2A-mediated lncRNA HCP5 Inhibits Gastric Cancer Progression via MiR-106b-5p/p21 Axis. Int J Biol Sci 2021;17:623-34. [PMID: 33613117 DOI: 10.7150/ijbs.55020] [Reference Citation Analysis]
4 Wang L, Miao C, He Y, Li H, Zhang S, Li K, Liu H, Li W, Zhao J, Xu Y, Tang H, Zhao Q, Stefan-van Staden R. The Influence of Heavy Metals on Gastric Tumorigenesis. Journal of Oncology 2022;2022:1-11. [DOI: 10.1155/2022/6425133] [Reference Citation Analysis]
5 Guo X, Zhao F, Ma X, Shen G, Ren D, Zheng F, Du F, Wang Z, Ahmad R, Yuan X, Zhao J, Zhao J. A comparison between triplet and doublet chemotherapy in improving the survival of patients with advanced gastric cancer: a systematic review and meta-analysis. BMC Cancer 2019;19:1125. [PMID: 31747911 DOI: 10.1186/s12885-019-6294-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
6 Song Y, Li N, Li Q, Liang X, Zhang S, Fan Q, Yin X, Zhuang Z, Liu Y, Zhang J, Kou X, Zhong H, Wang X, Dou Y, Huang J. HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial. J Immunother Cancer 2020;8:e001279. [PMID: 33060149 DOI: 10.1136/jitc-2020-001279] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Salapa J, Bushman A, Lowe K, Irudayaraj J. Nano drug delivery systems in upper gastrointestinal cancer therapy. Nano Converg 2020;7:38. [PMID: 33301056 DOI: 10.1186/s40580-020-00247-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
8 Kim JW, Kim JG, Kang BW, Chung IJ, Hong YS, Kim TY, Song HS, Lee KH, Zang DY, Ko YH, Song EK, Baek JH, Koo DH, Oh SY, Cho H, Lee KW. Treatment Patterns and Changes in Quality of Life during First-Line Palliative Chemotherapy in Korean Patients with Advanced Gastric Cancer. Cancer Res Treat 2019;51:223-39. [PMID: 30584995 DOI: 10.4143/crt.2018.073] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
9 Song J, Li Z, Chen P, Yu J, Wang F, Yang Z, Wang X. A 18FDG PET/CT-based volume parameter is a predictor of overall survival in patients with local advanced gastric cancer. Chin J Cancer Res 2019;31:632-40. [PMID: 31564806 DOI: 10.21147/j.issn.1000-9604.2019.04.07] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Johnston FM, Beckman M. Updates on Management of Gastric Cancer. Curr Oncol Rep 2019;21:67. [PMID: 31236716 DOI: 10.1007/s11912-019-0820-4] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 14.0] [Reference Citation Analysis]
11 Canbay E, Canbay Torun B, Cosarcan K, Altunal C, Gurbuz B, Bilgic C, Sezgin C, Kaban KK, Yilmaz S, Yazici Z. Surgery with hyperthermic intraperitoneal chemotherapy after response to induction chemotherapy in patients with peritoneal metastasis of gastric cancer. J Gastrointest Oncol 2021;12:S47-56. [PMID: 33968425 DOI: 10.21037/jgo-20-121] [Reference Citation Analysis]
12 Parisi A, Porzio G, Ficorella C. Multimodality Treatment in Metastatic Gastric Cancer: From Past to Next Future. Cancers (Basel) 2020;12:E2598. [PMID: 32932914 DOI: 10.3390/cancers12092598] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
13 Arslan C, Atilla FD. Modified docetaxel, cisplatin, and 5-fluorouracil combination regimen and capecitabine maintenance in metastatic gastric cancer: toxicity and efficacy results. Support Care Cancer 2022. [PMID: 35106659 DOI: 10.1007/s00520-022-06859-0] [Reference Citation Analysis]
14 Ni Q, Zhang Y, Tao R, Li X, Zhu J. MicroRNA-95-3p serves as a contributor to cisplatin resistance in human gastric cancer cells by targeting EMP1/PI3K/AKT signaling. Aging (Albany NY) 2021;13:8665-87. [PMID: 33714198 DOI: 10.18632/aging.202679] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Xiong Z, Lin Y, Yu Y, Zhou X, Fan J, Rog CJ, Cai K, Wang Z, Chang Z, Wang G, Tao K, Cai M. Exploration of Lipid Metabolism in Gastric Cancer: A Novel Prognostic Genes Expression Profile. Front Oncol 2021;11:712746. [PMID: 34568042 DOI: 10.3389/fonc.2021.712746] [Reference Citation Analysis]
16 Xu T, Wang M, Jiang L, Ma L, Wan L, Chen Q, Wei C, Wang Z. CircRNAs in anticancer drug resistance: recent advances and future potential. Mol Cancer 2020;19:127. [PMID: 32799866 DOI: 10.1186/s12943-020-01240-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 6.5] [Reference Citation Analysis]
17 Dalhammar K, Malmström M, Schelin M, Falkenback D, Kristensson J. The impact of initial treatment strategy and survival time on quality of end-of-life care among patients with oesophageal and gastric cancer: A population-based cohort study. PLoS One 2020;15:e0235045. [PMID: 32569329 DOI: 10.1371/journal.pone.0235045] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
18 Zhao R, Zhang X, Zhang Y, Zhang Y, Yang Y, Sun Y, Zheng X, Qu A, Umwali Y, Zhang Y. HOTTIP Predicts Poor Survival in Gastric Cancer Patients and Contributes to Cisplatin Resistance by Sponging miR-216a-5p. Front Cell Dev Biol 2020;8:348. [PMID: 32457911 DOI: 10.3389/fcell.2020.00348] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
19 Xu B, Li S, Fang Y, Zou Y, Song D, Zhang S, Cai Y. Proprotein Convertase Subtilisin/Kexin Type 9 Promotes Gastric Cancer Metastasis and Suppresses Apoptosis by Facilitating MAPK Signaling Pathway Through HSP70 Up-Regulation. Front Oncol 2020;10:609663. [PMID: 33489919 DOI: 10.3389/fonc.2020.609663] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
20 Zhang F, Zhang Y, Jia Z, Wu H, Gu K. Oxaliplatin-Based Regimen is Superior to Cisplatin-Based Regimen in Tumour Remission as First-line Chemotherapy for Advanced Gastric Cancer: A Meta-Analysis. J Cancer 2019;10:1923-9. [PMID: 31205551 DOI: 10.7150/jca.28896] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
21 Lee JG, Kim SA, Eun CS, Han DS, Kim YS, Choi BY, Song KS, Kim HJ, Park CH. Impact of age on stage-specific mortality in patients with gastric cancer: A long-term prospective cohort study. PLoS One 2019;14:e0220660. [PMID: 31369631 DOI: 10.1371/journal.pone.0220660] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
22 Naghavi L, Schwalbe M, Ghanem A, Naumann M. Deubiquitinylase USP47 Promotes RelA Phosphorylation and Survival in Gastric Cancer Cells. Biomedicines 2018;6:E62. [PMID: 29786670 DOI: 10.3390/biomedicines6020062] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
23 de Man FM, Goey AKL, van Schaik RHN, Mathijssen RHJ, Bins S. Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics. Clin Pharmacokinet. 2018;. [PMID: 29520731 DOI: 10.1007/s40262-018-0644-7] [Cited by in Crossref: 90] [Cited by in F6Publishing: 78] [Article Influence: 30.0] [Reference Citation Analysis]
24 van den Ende T, Ter Veer E, Machiels M, Mali RMA, Abe Nijenhuis FA, de Waal L, Laarman M, Gisbertz SS, Hulshof MCCM, van Oijen MGH, van Laarhoven HWM. The Efficacy and Safety of (Neo)Adjuvant Therapy for Gastric Cancer: A Network Meta-analysis. Cancers (Basel) 2019;11:E80. [PMID: 30641964 DOI: 10.3390/cancers11010080] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
25 Chevallay M, Wassmer CH, Iranmanesh P, Jung MK, Mönig SP. Multimodal treatment in oligometastatic gastric cancer. World J Gastrointest Oncol 2022; 14(2): 434-449 [DOI: 10.4251/wjgo.v14.i2.434] [Reference Citation Analysis]
26 Lv H, Zhang J, Sun K, Nie C, Chen B, Wang J, Xu W, Wang S, Liu Y, Chen X. Expression of Human Epidermal Growth Factor Receptor-2 Status and Programmed Cell Death Protein-1 Ligand Is Associated With Prognosis in Gastric Cancer. Front Oncol 2020;10:580045. [PMID: 33598422 DOI: 10.3389/fonc.2020.580045] [Reference Citation Analysis]
27 Qian H, Lv X, Song Q, Su R, Xie T, Wu D, Chang R, Chen L, Yang Y, Chen Y, Wang X, Ru Y, Shang L, Guo X. Association of dysbindin expression with individualized postoperative prognosis and chemotherapy benefit among patients with gastric adenocarcinoma. J Cancer 2021;12:6740-8. [PMID: 34659563 DOI: 10.7150/jca.60576] [Reference Citation Analysis]
28 Sun Y, Xie Y, Tang H, Ren Z, Luan X, Zhang Y, Zhu M, Lv Z, Bao H, Li Y, Liu R, Shen Y, Zheng Y, Pei J. In vitro and in vivo Evaluation of a Novel Estrogen-Targeted PEGylated Oxaliplatin Liposome for Gastric Cancer. Int J Nanomedicine 2021;16:8279-303. [PMID: 34992365 DOI: 10.2147/IJN.S340180] [Reference Citation Analysis]
29 Oh S, Kim E, Lee H. Comparative Impact of PD-1 and PD-L1 Inhibitors on Advanced Esophageal or Gastric/Gastroesophageal Junction Cancer Treatment: A Systematic Review and Meta-Analysis. J Clin Med 2021;10:3612. [PMID: 34441907 DOI: 10.3390/jcm10163612] [Reference Citation Analysis]
30 Cotes Sanchís A, Gallego J, Hernandez R, Arrazubi V, Custodio A, Cano JM, Aguado G, Macias I, Lopez C, López F, Visa L, Garrido M, Martínez Lago N, Fernández Montes A, Limón ML, Azkárate A, Pimentel P, Reguera P, Ramchandani A, Cacho JD, Martín Carnicero A, Granja M, Martín Richard M, Hernández Pérez C, Hurtado A, Serra O, Buxo E, Vidal Tocino R, Jimenez-Fonseca P, Carmona-Bayonas A. Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry. PLoS One 2020;15:e0235848. [PMID: 32735623 DOI: 10.1371/journal.pone.0235848] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Takeuchi M, Ajani JA, Fang X, Pfeiffer P, Takeuchi M, van Laarhoven HWM. Meta-Enrichment Analyses to Identify Advanced Gastric Cancer Patients Who Achieve a Higher Response to S-1/Cisplatin. Cancers (Basel) 2019;11:E871. [PMID: 31234436 DOI: 10.3390/cancers11060871] [Reference Citation Analysis]
32 Ma R, Shimura T, Yin C, Okugawa Y, Kitajima T, Koike Y, Okita Y, Ohi M, Uchida K, Goel A, Yao L, Zhang X, Toiyama Y. Antitumor effects of Andrographis via ferroptosis-associated genes in gastric cancer. Oncol Lett 2021;22:523. [PMID: 34025790 DOI: 10.3892/ol.2021.12784] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Khayamian MA, Shalileh S, Vanaei S, Salemizadeh Parizi M, Ansaryan S, Saghafi M, Abbasvandi F, Ebadi A, Soltan Khamsi P, Abdolahad M. Electrochemical generation of microbubbles by carbon nanotube interdigital electrodes to increase the permeability and material uptakes of cancer cells. Drug Deliv 2019;26:928-34. [PMID: 31526074 DOI: 10.1080/10717544.2019.1662514] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
34 Wang Y, Li G. Effects of S-1 combined with palliative care on immune function and quality of life of patients with advanced stomach cancer. Oncol Lett 2020;20:2021-7. [PMID: 32724449 DOI: 10.3892/ol.2020.11720] [Reference Citation Analysis]
35 Wang X, Xie L, Zhu L. Clinicopathological significance of HSP70 expression in gastric cancer: a systematic review and meta-analysis. BMC Gastroenterol 2021;21:437. [PMID: 34809574 DOI: 10.1186/s12876-021-01990-4] [Reference Citation Analysis]
36 Ter Veer E, van Oijen MGH, van Laarhoven HWM. The Use of (Network) Meta-Analysis in Clinical Oncology. Front Oncol 2019;9:822. [PMID: 31508373 DOI: 10.3389/fonc.2019.00822] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
37 Chang L, Gao H, Wang L, Wang N, Zhang S, Zhou X, Yang H. Exosomes derived from miR-1228 overexpressing bone marrow-mesenchymal stem cells promote growth of gastric cancer cells. Aging (Albany NY) 2021;13:11808-21. [PMID: 33883305 DOI: 10.18632/aging.202878] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
38 McGee SF, AlGhareeb W, Ahmad CH, Armstrong D, Babak S, Berry S, Biagi J, Booth C, Bossé D, Champion P, Colwell B, Finn N, Goel R, Gray S, Green J, Harb M, Hyde A, Jeyakumar A, Jonker D, Kanagaratnam S, Kavan P, MacMillan A, Muinuddin A, Patil N, Porter G, Powell E, Ramjeesingh R, Raza M, Rorke S, Seal M, Servidio-Italiano F, Siddiqui J, Simms J, Smithson L, Snow S, St-Hilaire E, Stuckless T, Tate A, Tehfe M, Thirlwell M, Tsvetkova E, Valdes M, Vickers M, Virik K, Welch S, Marginean C, Asmis T. Eastern Canadian Colorectal Cancer Consensus Conference 2017. Curr Oncol 2018;25:262-74. [PMID: 30111967 DOI: 10.3747/co.25.4083] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
39 Ma Z, Liu G, Hao S, Zhao T, Chang W, Wang J, Ren H, Zhao X, Chen G. PITPNA-AS1/miR-98-5p to Mediate the Cisplatin Resistance of Gastric Cancer. Journal of Oncology 2022;2022:1-14. [DOI: 10.1155/2022/7981711] [Reference Citation Analysis]
40 Viúdez A, Carmona-Bayonas A, Gallego J, Lacalle A, Hernández R, Cano JM, Macías I, Custodio A, Martínez de Castro E, Sánchez A, Iglesia L, Reguera P, Visa L, Azkarate A, Sánchez-Cánovas M, Mangas M, Limón ML, Martínez-Torrón A, Asensio E, Ramchandani A, Martín-Carnicero A, Hurtado A, Cerdà P, Garrido M, Sánchez-Bayonas R, Serrano R, Jiménez-Fonseca P; AGAMENON Study Group. Optimal duration of first-line chemotherapy for advanced gastric cancer: data from the AGAMENON registry. Clin Transl Oncol 2020;22:734-50. [PMID: 31385226 DOI: 10.1007/s12094-019-02183-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
41 Chen C, Zhang F, Zhou N, Gu YM, Zhang YT, He YD, Wang L, Yang LX, Zhao Y, Li YM. Efficacy and safety of immune checkpoint inhibitors in advanced gastric or gastroesophageal junction cancer: a systematic review and meta-analysis. Oncoimmunology. 2019;8:e1581547. [PMID: 31069144 DOI: 10.1080/2162402x.2019.1581547] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
42 Li Y, Liu H, Cui Y, Chen H, Cui X, Shao J, Su F, He X. miR-424-3p Contributes to the Malignant Progression and Chemoresistance of Gastric Cancer. Onco Targets Ther 2020;13:12201-11. [PMID: 33273826 DOI: 10.2147/OTT.S280717] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
43 Chang TS, Lu CK, Hsieh YY, Wei KL, Chen WM, Tung SY, Wu CS, Chan MWY, Chiang MK. 2,4-Diamino-Quinazoline, a Wnt Signaling Inhibitor, Suppresses Gastric Cancer Progression and Metastasis. Int J Mol Sci 2020;21:E5901. [PMID: 32824603 DOI: 10.3390/ijms21165901] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
44 Yang JC, Chang N, Wu DC, Cheng WC, Chung WM, Chang WC, Lei FJ, Liu CJ, Wu IC, Lai HC, Ma WL. Preclinical evaluation of exemestane as a novel chemotherapy for gastric cancer. J Cell Mol Med 2019;23:7417-26. [PMID: 31557413 DOI: 10.1111/jcmm.14605] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
45 Klaassen R, Larue RTHM, Mearadji B, van der Woude SO, Stoker J, Lambin P, van Laarhoven HWM. Feasibility of CT radiomics to predict treatment response of individual liver metastases in esophagogastric cancer patients. PLoS One 2018;13:e0207362. [PMID: 30440002 DOI: 10.1371/journal.pone.0207362] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
46 Senthil M. Quality-of-Life Assessment in Patients Receiving Palliative Chemotherapy: Call for Action. Ann Surg Oncol 2021;28:7-8. [PMID: 33140253 DOI: 10.1245/s10434-020-09297-6] [Reference Citation Analysis]
47 Yuan L, Xu ZY, Ruan SM, Mo S, Qin JJ, Cheng XD. Long non-coding RNAs towards precision medicine in gastric cancer: early diagnosis, treatment, and drug resistance. Mol Cancer. 2020;19:96. [PMID: 32460771 DOI: 10.1186/s12943-020-01219-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 33] [Article Influence: 13.5] [Reference Citation Analysis]
48 Arbabi Moghadam S, Rezania V, Tuszynski JA. Cell death and survival due to cytotoxic exposure modelled as a two-state Ising system. R Soc Open Sci 2020;7:191578. [PMID: 32257323 DOI: 10.1098/rsos.191578] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Yu S, Wang Y, Peng K, Lyu M, Liu F, Liu T. Establishment of a Prognostic Signature of Stromal/Immune-Related Genes for Gastric Adenocarcinoma Based on ESTIMATE Algorithm. Front Cell Dev Biol 2021;9:752023. [PMID: 34900998 DOI: 10.3389/fcell.2021.752023] [Reference Citation Analysis]
50 Yue C, Yu C, Peng R, Wang J, Li G, Xu L. LINC00665/miR-379-5p/GRP78 regulates cisplatin sensitivity in gastric cancer by modulating endoplasmic reticulum stress. Cytotechnology 2021;73:413-22. [PMID: 34149174 DOI: 10.1007/s10616-021-00466-3] [Reference Citation Analysis]
51 Zhao K, Wang Z, Li X, Liu JL, Tian L, Chen JQ. Exosome-mediated transfer of CLIC1 contributes to the vincristine-resistance in gastric cancer. Mol Cell Biochem 2019;462:97-105. [PMID: 31473882 DOI: 10.1007/s11010-019-03613-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
52 Pang X, Zhou Z, Yu Z, Han L, Lin Z, Ao X, Liu C, He Y, Ponnusamy M, Li P, Wang J. Foxo3a-dependent miR-633 regulates chemotherapeutic sensitivity in gastric cancer by targeting Fas-associated death domain. RNA Biol 2019;16:233-48. [PMID: 30628514 DOI: 10.1080/15476286.2019.1565665] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
53 Yalikong A, Li XQ, Zhou PH, Qi ZP, Li B, Cai SL, Zhong YS. A Triptolide Loaded HER2-Targeted Nano-Drug Delivery System Significantly Suppressed the Proliferation of HER2-Positive and BRAF Mutant Colon Cancer. Int J Nanomedicine 2021;16:2323-35. [PMID: 33776436 DOI: 10.2147/IJN.S287732] [Reference Citation Analysis]
54 Wang YN, Chang SY, Hwang JM, Chang YK, Kao WY, Wan HL, Tzeng IS, Wu CC. Evaluating the benefit of adjuvant radiotherapy after extensive lymph node dissection for gastric cancer: a single-institute retrospective study. Tzu Chi Med J 2021;33:288-93. [PMID: 34386368 DOI: 10.4103/tcmj.tcmj_230_20] [Reference Citation Analysis]
55 Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P, Ott PA, Peltola K, Jaeger D, Evans J, de Braud F, Chau I, Harbison CT, Dorange C, Tschaika M, Le DT. CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. J Clin Oncol. 2018;36:2836-2844. [PMID: 30110194 DOI: 10.1200/jco.2017.76.6212] [Cited by in Crossref: 215] [Cited by in F6Publishing: 152] [Article Influence: 53.8] [Reference Citation Analysis]
56 Tang H, Huang W, Yang Q, Lin Y, Chen Y, Shu P. Jianpi Yangwei decoction promotes apoptosis and suppresses proliferation of 5-fluorouracil resistant gastric cancer cells in vitro and in vivo. BMC Complement Med Ther 2020;20:337. [PMID: 33167958 DOI: 10.1186/s12906-020-03135-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
57 Santero M, Pérez-Bracchiglione J, Acosta-Dighero R, Meade AG, Antequera A, Auladell-Rispau A, Quintana MJ, Requeijo C, Rodríguez-Grijalva G, Salas-Gama K, Dorantes-Romandia R, Salazar J, Solà I, Urrútia G, Bonfill Cosp X. Efficacy of systemic oncological treatments in patients with advanced esophageal or gastric cancers at high risk of dying in the middle and short term: an overview of systematic reviews. BMC Cancer 2021;21:712. [PMID: 34134661 DOI: 10.1186/s12885-021-08330-5] [Reference Citation Analysis]
58 Vasista A, Stockler M, Martin A, Pavlakis N, Sjoquist K, Goldstein D, Gill S, Jain V, Liu G, Kannourakis G, Kim YH, Nott L, Snow S, Burge M, Harris D, Jonker D, Chua YJ, Epstein R, Bonaventura A, Kiely B. Accuracy and Prognostic Significance of Oncologists' Estimates and Scenarios for Survival Time in Advanced Gastric Cancer. Oncologist 2019;24:e1102-7. [PMID: 30936377 DOI: 10.1634/theoncologist.2018-0613] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
59 Bang YJ, Ruiz EY, Van Cutsem E, Lee KW, Wyrwicz L, Schenker M, Alsina M, Ryu MH, Chung HC, Evesque L, Al-Batran SE, Park SH, Lichinitser M, Boku N, Moehler MH, Hong J, Xiong H, Hallwachs R, Conti I, Taieb J. Phase III, randomised trial of avelumab vs physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. Ann Oncol. 2018;29:2052-2060. [PMID: 30052729 DOI: 10.1093/annonc/mdy264] [Cited by in Crossref: 169] [Cited by in F6Publishing: 175] [Article Influence: 56.3] [Reference Citation Analysis]
60 Lengyel CG, Hussain S, Seeber A, Jamil Nidhamalddin S, Trapani D, Habeeb BS, Elfaham E, Mazher SA, Seid F, Khan SZ, El Bairi K, Odhiambo A, Altuna SC, Petrillo A. FGFR Pathway Inhibition in Gastric Cancer: The Golden Era of an Old Target? Life (Basel) 2022;12:81. [PMID: 35054474 DOI: 10.3390/life12010081] [Reference Citation Analysis]
61 Rosenberg AJ, Rademaker A, Hochster HS, Ryan T, Hensing T, Shankaran V, Baddi L, Mahalingam D, Mulcahy MF, Benson AB 3rd. Docetaxel, Oxaliplatin, and 5-Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long-Term Follow-Up. Oncologist 2019;24:1039-e642. [PMID: 31138725 DOI: 10.1634/theoncologist.2019-0330] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
62 Berger AK, Allgäuer M, Apostolidis L, Schulze-Schleithoff AE, Merle U, Jaeger D, Haag GM. Cancer-related microangiopathic hemolytic anemia in patients with advanced gastric cancer: A retrospective single-center analysis. World J Gastrointest Oncol 2020; 12(11): 1288-1295 [PMID: 33250961 DOI: 10.4251/wjgo.v12.i11.1288] [Cited by in CrossRef: 1] [Article Influence: 0.5] [Reference Citation Analysis]
63 Peixoto RD, Rocha-Filho DR, Weschenfelder RF, Rego JFM, Riechelmann R, Coutinho AK, Fernandes GS, Jacome AA, Andrade AC, Murad AM, Mello CAL, Miguel DSCG, Gomes DBD, Racy DJ, Moraes ED, Akaishi EH, Carvalho ES, Mello ES, Filho FM, Coimbra FJF, Capareli FC, Arruda FF, Vieira FMAC, Takeda FR, Cotti GCC, Pereira GLS, Paulo GA, Ribeiro HSC, Lourenco LG, Crosara M, Toneto MG, Oliveira MB, de Lourdes Oliveira M, Begnami MD, Forones NM, Yagi O, Ashton-Prolla P, Aguillar PB, Amaral PCG, Hoff PM, Araujo RLC, Filho RPDP, Gansl RC, Gil RA, Pfiffer TEF, Souza T, Jr UR, Jesus VHF, Jr WLC, Prolla G. Brazilian Group of Gastrointestinal Tumours' consensus guidelines for the management of gastric cancer. Ecancermedicalscience 2020;14:1126. [PMID: 33209117 DOI: 10.3332/ecancer.2020.1126] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
64 Wang Z, Zhang L, Wang J, Wang Y, Dong Q, Piao H, Wang Q, Zhang J. Prealbumin-to-Globulin Ratio Can Predict the Chemotherapy Outcomes and Prognosis of Patients with Gastric Cancer Receiving First-Line Chemotherapy. J Immunol Res 2020;2020:6813176. [PMID: 32832571 DOI: 10.1155/2020/6813176] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
65 Song S, Xu Y, Huo L, Zhao S, Wang R, Li Y, Scott AW, Pizzi MP, Wang Y, Fan Y, Harada K, Jin J, Ma L, Yao X, Shanbhag ND, Gan Q, Roy-Chowdhuri S, Badgwell BD, Wang Z, Wang L, Ajani JA. Patient-derived cell lines and orthotopic mouse model of peritoneal carcinomatosis recapitulate molecular and phenotypic features of human gastric adenocarcinoma. J Exp Clin Cancer Res 2021;40:207. [PMID: 34162421 DOI: 10.1186/s13046-021-02003-8] [Reference Citation Analysis]
66 Sethi NS, Kikuchi O, Duronio GN, Stachler MD, McFarland JM, Ferrer-Luna R, Zhang Y, Bao C, Bronson R, Patil D, Sanchez-Vega F, Liu JB, Sicinska E, Lazaro JB, Ligon KL, Beroukhim R, Bass AJ. Early TP53 alterations engage environmental exposures to promote gastric premalignancy in an integrative mouse model. Nat Genet 2020;52:219-30. [PMID: 32025000 DOI: 10.1038/s41588-019-0574-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
67 Sun T, Li K, Zhu K, Yan R, Dang C, Yuan D. SNHG6 Interacted with miR-325-3p to Regulate Cisplatin Resistance of Gastric Cancer by Targeting GITR. Onco Targets Ther 2020;13:12181-93. [PMID: 33268996 DOI: 10.2147/OTT.S262896] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
68 Coelho RC, Abreu PDP, Monteiro MR, Stramosk AP, Garces AHI, Melo AC, Graudenz MS, Andrade CJC. Cisplatin, Fluorouracil in Bolus Injection, and Leucovorin in First-Line Therapy for Advanced Gastric Cancer as an Alternative to Protocols With Infusional Fluorouracil. J Glob Oncol 2019;5:1-8. [PMID: 30668271 DOI: 10.1200/JGO.18.00176] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
69 Rimini M, Pecchi A, Prampolini F, Bussei C, Salati M, Forni D, Martelli F, Valoriani F, Canino F, Bocconi A, Gelsomino F, Reverberi L, Benatti S, Piacentini F, Menozzi R, Dominici M, Luppi G, Spallanzani A. The Prognostic Role of Early Skeletal Muscle Mass Depletion in Multimodality Management of Patients with Advanced Gastric Cancer Treated with First Line Chemotherapy: A Pilot Experience from Modena Cancer Center. J Clin Med 2021;10:1705. [PMID: 33921004 DOI: 10.3390/jcm10081705] [Reference Citation Analysis]
70 Wang Y, Cheng X, Cui YH, Hou J, Ji Y, Sun YH, Shen ZB, Liu FL, Liu TS. Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis. BMC Cancer 2018;18:702. [PMID: 29954358 DOI: 10.1186/s12885-018-4615-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
71 Chivu-Economescu M, Matei L, Necula LG, Dragu DL, Bleotu C, Diaconu CC. New therapeutic options opened by the molecular classification of gastric cancer. World J Gastroenterol 2018; 24(18): 1942-1961 [PMID: 29760539 DOI: 10.3748/wjg.v24.i18.1942] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
72 Hasegawa T, Sugihara T, Hoshino Y, Tarumoto R, Matsuki Y, Kanda T, Takata T, Nagahara T, Matono T, Isomoto H. Photosensitizer verteporfin inhibits the growth of YAP- and TAZ-dominant gastric cancer cells by suppressing the anti-apoptotic protein Survivin in a light-independent manner. Oncol Lett 2021;22:703. [PMID: 34457058 DOI: 10.3892/ol.2021.12964] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 Ishak NS, Abdul Rahman H, Lee SHF, Lu SK, Naing L. Incidence, Survival and Prognostic Factors of Oesophagogastric Cancer. J Gastrointest Cancer 2021. [PMID: 33392958 DOI: 10.1007/s12029-020-00559-w] [Reference Citation Analysis]
74 Sissung TM, Cordes L, Peer CJ, Gandhy S, Redman J, Strauss J, Figg WD. Case report: severe toxicity in an African-American patient receiving FOLFOX carrying uncommon allelic variants in DPYD. Pharmacogenomics 2021;22:81-5. [PMID: 33305610 DOI: 10.2217/pgs-2020-0120] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 . Gemeinsame Stellungnahme der DGHO und DGVS zur Nutzenbewertung von Nivolumab in Kombination mit Chemotherapie (Adenokarzinom von Ösophagus, gastroösophagealem Übergang und Magen). Z Gastroenterol 2022;60:862-6. [DOI: 10.1055/a-1826-5640] [Reference Citation Analysis]
76 Wang T, Zhang P, Li C, Liu W, Shen Q, Yang L, Xie G, Bai J, Li R, Tao K, Yin Y. MUS81 Inhibition Enhances the Anticancer Efficacy of Talazoparib by Impairing ATR/CHK1 Signaling Pathway in Gastric Cancer. Front Oncol 2022;12:844135. [DOI: 10.3389/fonc.2022.844135] [Reference Citation Analysis]
77 Shu X, Zhan PP, Sun LX, Yu L, Liu J, Sun LC, Yang ZH, Ran YL, Sun YM. BCAT1 Activates PI3K/AKT/mTOR Pathway and Contributes to the Angiogenesis and Tumorigenicity of Gastric Cancer. Front Cell Dev Biol 2021;9:659260. [PMID: 34164393 DOI: 10.3389/fcell.2021.659260] [Reference Citation Analysis]
78 Kim TH, Do Cho H, Choi YW, Lee HW, Kang SY, Jeong GS, Choi JH, Ahn MS, Sheen SS. Trastuzumab-based palliative chemotherapy for HER2-positive gastric cancer: a single-center real-world data. BMC Cancer 2021;21:325. [PMID: 33771119 DOI: 10.1186/s12885-021-08058-2] [Reference Citation Analysis]
79 El Rami FE, Barsoumian HB, Khneizer GW. Hereditary diffuse gastric cancer therapeutic roadmap: current and novel approaches in a nutshell. Ther Adv Med Oncol 2020;12:1758835920967238. [PMID: 33193828 DOI: 10.1177/1758835920967238] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
80 Jeong O, Jung MR, Kang JH. Treatment Modality Based Survival in Gastric Carcinoma Patients with Stand-Alone Peritoneal Metastasis: a Case-Control Study. J Gastric Cancer 2021;21:122-31. [PMID: 34234974 DOI: 10.5230/jgc.2021.21.e12] [Reference Citation Analysis]
81 Sun L, Wang H, Liu Z, Meng Y, Qiu M, Ju Y, Zhang S. Outcomes of 596 Advanced Gastric Cancer Patients with Different Numbers of Chemotherapy Lines: The More Chemotherapy Lines, the Better Survival. Cancer Manag Res 2020;12:10631-8. [PMID: 33149671 DOI: 10.2147/CMAR.S275990] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
82 Schokker S, van der Woude SO, van Kleef JJ, van Zoen DJ, van Oijen MGH, Mearadji B, Beenen LFM, Stroes CI, Waasdorp C, Jibodh RA, Creemers A, Meijer SL, Hooijer GKJ, Punt CJA, Bijlsma MF, van Laarhoven HWM. Phase I Dose Escalation Study with Expansion Cohort of the Addition of Nab-Paclitaxel to Capecitabine and Oxaliplatin (CapOx) as First-Line Treatment of Metastatic Esophagogastric Adenocarcinoma (ACTION Study). Cancers (Basel) 2019;11:E827. [PMID: 31207904 DOI: 10.3390/cancers11060827] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
83 Pan T, Yu Z, Jin Z, Wu X, Wu A, Hou J, Chang X, Fan Z, Li J, Yu B, Li F, Yan C, Yang Z, Zhu Z, Liu B, Su L. Tumor suppressor lnc-CTSLP4 inhibits EMT and metastasis of gastric cancer by attenuating HNRNPAB-dependent Snail transcription. Mol Ther Nucleic Acids 2021;23:1288-303. [PMID: 33717650 DOI: 10.1016/j.omtn.2021.02.003] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
84 Baxter MA, Petty RD, Swinson D, Hall PS, O'Hanlon S. Real‑world challenge for clinicians treating advanced gastroesophageal adenocarcinoma (Review). Int J Oncol 2021;58:22. [PMID: 33760115 DOI: 10.3892/ijo.2021.5202] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
85 Olnes MJ, Martinson HA. Recent advances in immune therapies for gastric cancer. Cancer Gene Ther 2021. [PMID: 33664460 DOI: 10.1038/s41417-021-00310-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
86 Hennessy MA, Hamid M, Keegan NM, Corrigan L, Goggin C, Oo NM, Carrigan M, Mockler D, O'Donovan A, Horgan AM. Metastatic gastroesophageal cancer in older patients - is this patient cohort represented in clinical trials? BMC Cancer 2022;22:3. [PMID: 34980003 DOI: 10.1186/s12885-021-09103-w] [Reference Citation Analysis]
87 Pan T, Jin Z, Yu Z, Wu X, Chang X, Fan Z, Li F, Wang X, Li Z, Zhou Q, Li J, Liu B, Su L. Cathepsin L promotes angiogenesis by regulating the CDP/Cux/VEGF-D pathway in human gastric cancer. Gastric Cancer 2020;23:974-87. [PMID: 32388635 DOI: 10.1007/s10120-020-01080-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
88 Li J, Zhang XH, Bei SH, Feng L. PD-1/PD-L1 antagonists in gastric cancer: Current studies and perspectives. World J Meta-Anal 2019; 7(3): 101-109 [DOI: 10.13105/wjma.v7.i3.101] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
89 Li Y, Wang P, Wu LL, Yan J, Pang XY, Liu SJ. miR-26a-5p Inhibit Gastric Cancer Cell Proliferation and Invasion Through Mediated Wnt5a. Onco Targets Ther 2020;13:2537-50. [PMID: 32273724 DOI: 10.2147/OTT.S241199] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
90 Fang QL, Li KC, Wang L, Gu XL, Song RJ, Lu S. Targeted Inhibition of CCL22 by miR-130a-5p Can Enhance the Sensitivity of Cisplatin-Resistant Gastric Cancer Cells to Chemotherapy. Cancer Manag Res 2020;12:3865-75. [PMID: 32547223 DOI: 10.2147/CMAR.S249738] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
91 Martin SP, Drake JA, Hernandez JM, Davis JL. Bidirectional chemotherapy in patients with gastric cancer and peritoneal metastasis. J Gastrointest Oncol 2020;11:108-11. [PMID: 32175112 DOI: 10.21037/jgo.2019.11.05] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
92 Ortiz N, Díaz C. Mevalonate pathway as a novel target for the treatment of metastatic gastric cancer. Oncol Lett 2020;20:320. [PMID: 33093924 DOI: 10.3892/ol.2020.12183] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
93 Cerles O, Gonçalves TC, Chouzenoux S, Benoit E, Schmitt A, Bennett Saidu NE, Kavian N, Chéreau C, Gobeaux C, Weill B, Coriat R, Nicco C, Batteux F. Preventive action of benztropine on platinum-induced peripheral neuropathies and tumor growth. Acta Neuropathol Commun 2019;7:9. [PMID: 30657060 DOI: 10.1186/s40478-019-0657-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
94 Zhao L, Li J, Bai C, Nie Y, Lin G. Multi-Modality Treatment for Patients With Metastatic Gastric Cancer: A Real-World Study in China. Front Oncol 2019;9:1155. [PMID: 31737573 DOI: 10.3389/fonc.2019.01155] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
95 Maron SB, Chase LM, Lomnicki S, Kochanny S, Moore KL, Joshi SS, Landron S, Johnson J, Kiedrowski LA, Nagy RJ, Lanman RB, Kim ST, Lee J, Catenacci DVT. Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma. Clin Cancer Res 2019;25:7098-112. [PMID: 31427281 DOI: 10.1158/1078-0432.CCR-19-1704] [Cited by in Crossref: 44] [Cited by in F6Publishing: 23] [Article Influence: 14.7] [Reference Citation Analysis]
96 Huo J, Wu L, Zang Y. Development and Validation of a Robust Immune-Related Prognostic Signature for Gastric Cancer. J Immunol Res 2021;2021:5554342. [PMID: 34007851 DOI: 10.1155/2021/5554342] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
97 Cheng J, Cai M, Shuai X, Gao J, Wang G, Tao K. First-line systemic therapy for advanced gastric cancer: a systematic review and network meta-analysis. Ther Adv Med Oncol 2019;11:1758835919877726. [PMID: 31632469 DOI: 10.1177/1758835919877726] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
98 Smyth EC, Fitzgerald RC. MUC16 Mutations and Prognosis in Gastric Cancer: A Little Goes a Long Way. JAMA Oncol 2018;4:1698-9. [PMID: 30098141 DOI: 10.1001/jamaoncol.2018.2803] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
99 Garg PK, Jara M, Alberto M, Rau B. The role of Pressurized IntraPeritoneal Aerosol Chemotherapy in the management of gastric cancer: A systematic review. Pleura Peritoneum 2019;4:20180127. [PMID: 31198852 DOI: 10.1515/pp-2018-0127] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
100 Aigner K, Vashist YK, Selak E, Gailhofer S, Aigner KR. Efficacy of Regional Chemotherapy Approach in Peritoneal Metastatic Gastric Cancer. J Clin Med 2021;10:5322. [PMID: 34830604 DOI: 10.3390/jcm10225322] [Reference Citation Analysis]
101 van Kleef JJ, van den Boorn HG, Verhoeven RHA, Vanschoenbeek K, Abu-Hanna A, Zwinderman AH, Sprangers MAG, van Oijen MGH, De Schutter H, van Laarhoven HWM. External Validation of the Dutch SOURCE Survival Prediction Model in Belgian Metastatic Oesophageal and Gastric Cancer Patients. Cancers (Basel) 2020;12:E834. [PMID: 32244310 DOI: 10.3390/cancers12040834] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
102 Wang X, Xu Z, Sun J, Lv H, Wang Y, Ni Y, Chen S, Hu C, Wang L, Chen W, Cheng X. Cisplatin resistance in gastric cancer cells is involved with GPR30-mediated epithelial-mesenchymal transition. J Cell Mol Med 2020;24:3625-33. [PMID: 32052561 DOI: 10.1111/jcmm.15055] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
103 Gong X, Xu B, Zi L, Chen X. miR-625 reverses multidrug resistance in gastric cancer cells by directly targeting ALDH1A1. Cancer Manag Res. 2019;11:6615-6624. [PMID: 31410057 DOI: 10.2147/cmar.s208708] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
104 Li Y, Xie D, Chen X, Hu T, Lu S, Han Y. Prognostic Value of the Site of Distant Metastasis and Surgical Interventions in Metastatic Gastric Cancer: A Population-Based Study. Technol Cancer Res Treat 2020;19:1533033820964131. [PMID: 33111644 DOI: 10.1177/1533033820964131] [Reference Citation Analysis]
105 Jimenez-Fonseca P, Carmona-Bayonas A, Martínez de Castro E, Custodio A, Pericay Pijaume C, Hernandez R, Aguado G, Castro Unanua N, Cano JM, López F, Garrido M, Fernández Montes A, Visa L, Sánchez Cánovas M, Limón ML, Martínez Lago N, Pimentel P, Hurtado A, Azkárate A, Longo F, Diez M, Arias-Martinez A, Sauri T, Martín Carnicero A, Mangas M, Martín Richard M, Granja M, Ramchandani A, Hernández Pérez C, Cerdá P, Gil-Negrete A, Calvo M, Vidal Tocino R, Gallego J. External validity of docetaxel triplet trials in advanced gastric cancer: are there patients who still benefit? Gastric Cancer 2021;24:445-56. [PMID: 32970266 DOI: 10.1007/s10120-020-01116-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
106 Zhou Q, Lan X, Li N, Yuan D, Zhang J. Analysis of Prognostic Factors and Design of Prognosis Model for Patients with Stage IV Gastric Cancer Following First-Line Palliative Chemotherapy. Cancer Manag Res 2020;12:10461-8. [PMID: 33122945 DOI: 10.2147/CMAR.S263320] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
107 Halpern N, Grinshpun A, Boursi B, Golan T, Margalit O, Aderka D, Friedman E, Laitman Y, Hubert A, Kadouri L, Hamburger T, Barnes-Kedar I, Levi Z, Ben-Aharon I, Brenner B, Goldberg Y, Peretz T, Shacham-Shmueli E. Clinical Characteristics and Prognosis of Gastric Cancer Patients with BRCA 1/2 Germline Mutations: Report of Ten Cases and a Literature Review. Onco Targets Ther. 2020;13:11637-11644. [PMID: 33235458 DOI: 10.2147/ott.s276814] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
108 Yang H, Zhou Y, Wang L, Gu T, Lv M, Sun J, Tu C, He J. The Efficacy of Ramucirumab in the Treatment of Gastric or Gastroesophageal Junction Cancer: A Meta-Analysis of RCTs. Gastroenterol Res Pract 2021;2021:8960315. [PMID: 33679971 DOI: 10.1155/2021/8960315] [Reference Citation Analysis]
109 Huang Q, Zheng X, Jiao Y, Lei Y, Li X, Bi F, Guo F, Wang G, Liu M. A Distinct Clinicopathological Feature and Prognosis of Young Gastric Cancer Patients Aged ≤ 45 Years Old. Front Oncol 2021;11:674224. [PMID: 34513668 DOI: 10.3389/fonc.2021.674224] [Reference Citation Analysis]
110 Jiang Y, Li Y, Wang LXW. Cost-effectiveness analysis of nivolumab plus standard chemotherapy versus chemotherapy alone for the first-line treatment of unresectable advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. Int J Clin Pharm 2022. [PMID: 35088231 DOI: 10.1007/s11096-021-01372-6] [Reference Citation Analysis]
111 Mondaca S, Margolis M, Sanchez-Vega F, Jonsson P, Riches JC, Ku GY, Hechtman JF, Tuvy Y, Berger MF, Shah MA, Kelsen DP, Ilson DH, Yu K, Goldberg Z, Epstein AS, Desai A, Chung V, Chou JF, Capanu M, Solit DB, Schultz N, Janjigian YY. Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer. Gastric Cancer 2019;22:355-62. [PMID: 30088161 DOI: 10.1007/s10120-018-0861-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
112 Suo RY, Wang ZY, Wang JS, Zhang GJ, Zhang J. Role of long non-coding RNA in regulating polarization of gastric cancer macrophages. Shijie Huaren Xiaohua Zazhi 2021; 29(19): 1096-1101 [DOI: 10.11569/wcjd.v29.i19.1096] [Reference Citation Analysis]
113 Zhou X, Liu M, Ren Q, Zhu W, Wang Y, Chen H, Chen J. Oral and injectable Marsdenia tenacissima extract (MTE) as adjuvant therapy to chemotherapy for gastric cancer: a systematic review. BMC Complement Altern Med 2019;19:366. [PMID: 31830977 DOI: 10.1186/s12906-019-2779-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
114 Wu R, Guo S, Lai S, Pan G, Zhang L, Liu H. A stable gene set for prediction of prognosis and efficacy of chemotherapy in gastric cancer. BMC Cancer 2021;21:684. [PMID: 34112138 DOI: 10.1186/s12885-021-08444-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
115 Legué LM, Bernards N, Lemmens VE, de Hingh IH, Creemers GJ, van Erning FN. Palliative chemotherapy for patients with synchronous metastases of small-bowel adenocarcinoma: A reflection of daily practice. United European Gastroenterol J 2019;7:1380-8. [PMID: 31839964 DOI: 10.1177/2050640619858211] [Reference Citation Analysis]
116 Wang J, Wu DX, Meng L, Ji G. Anlotinib combined with SOX regimen (S1 (tegafur, gimeracil and oteracil porassium capsules) + oxaliplatin) in treating stage IV gastric cancer: study protocol for a single-armed and single-centred clinical trial. BMJ Open 2020;10:e034685. [PMID: 32499264 DOI: 10.1136/bmjopen-2019-034685] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
117 Favero G, Moretti E, Bonomini F, Reiter RJ, Rodella LF, Rezzani R. Promising Antineoplastic Actions of Melatonin. Front Pharmacol 2018;9:1086. [PMID: 30386235 DOI: 10.3389/fphar.2018.01086] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 7.8] [Reference Citation Analysis]
118 Ke X, Qin Q, Deng T, Liao Y, Gao SJ. Heterogeneous Responses of Gastric Cancer Cell Lines to Tenovin-6 and Synergistic Effect with Chloroquine. Cancers (Basel) 2020;12:E365. [PMID: 32033497 DOI: 10.3390/cancers12020365] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
119 Shreyash N, Sonker M, Bajpai S, Tiwary SK. Review of the Mechanism of Nanocarriers and Technological Developments in the Field of Nanoparticles for Applications in Cancer Theragnostics. ACS Appl Bio Mater 2021;4:2307-34. [PMID: 35014353 DOI: 10.1021/acsabm.1c00020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 7.0] [Reference Citation Analysis]
120 Mulder K, Lim H, Ravi D, Ahmed S, Brunet B, Davies J, Doll C, Dueck D, Gordon V, Hebbard P, Kim CA, Le D, Lee-ying R, Mcghie JP, Park J, Renouf DJ, Schellenberg D, Wong RPW, Zaidi A, Ahmed S. Current Role of Immunotherapy in Gastric, Esophageal and Gastro-Esophageal Junction Cancers—A Report from the Western Canadian Gastrointestinal Cancer Consensus Conference. Current Oncology 2022;29:3160-70. [DOI: 10.3390/curroncol29050257] [Reference Citation Analysis]
121 Moehler M, Dvorkin M, Boku N, Özgüroğlu M, Ryu MH, Muntean AS, Lonardi S, Nechaeva M, Bragagnoli AC, Coşkun HS, Cubillo Gracian A, Takano T, Wong R, Safran H, Vaccaro GM, Wainberg ZA, Silver MR, Xiong H, Hong J, Taieb J, Bang YJ. Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100. J Clin Oncol 2021;39:966-77. [PMID: 33197226 DOI: 10.1200/JCO.20.00892] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
122 Park H, Jin RU, Wang-Gillam A, Suresh R, Rigden C, Amin M, Tan BR, Pedersen KS, Lim KH, Trikalinos NA, Acharya A, Copsey ML, Navo KA, Morton AE, Gao F, Lockhart AC. FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial. JAMA Oncol 2020;6:1231-40. [PMID: 32469386 DOI: 10.1001/jamaoncol.2020.2020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
123 Koyama N, Katayanagi S, Kawachi S. Pre-existing interstitial lung disease as a risk factor for pneumonitis associated with ramucirumab and paclitaxel in patients with gastric cancer: The impact of usual interstitial pneumonia. PLoS One 2018;13:e0198886. [PMID: 29879213 DOI: 10.1371/journal.pone.0198886] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
124 Mehta R, Kommalapati A, Kim RD. The Impact of Ramucirumab Treatment on Survival and Quality of Life in Patients with Gastric Cancer. Cancer Manag Res 2020;12:51-7. [PMID: 32021422 DOI: 10.2147/CMAR.S199827] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
125 Ren M, Zhou X, Gu M, Jiao W, Yu M, Wang Y, Liu S, Yang J, Ji F. Resveratrol synergizes with cisplatin in antineoplastic effects against AGS gastric cancer cells by inducing endoplasmic reticulum stress‑mediated apoptosis and G2/M phase arrest. Oncol Rep 2020;44:1605-15. [PMID: 32945472 DOI: 10.3892/or.2020.7708] [Reference Citation Analysis]
126 Zhou KI, Peterson B, Serritella A, Thomas J, Reizine N, Moya S, Tan C, Wang Y, Catenacci DVT. Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy. Clin Cancer Res 2020;26:6453-63. [PMID: 32820017 DOI: 10.1158/1078-0432.CCR-20-2085] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 8.5] [Reference Citation Analysis]
127 Lei Z, Wang J, Li Z, Li B, Luo J, Wang X, Wang J, Ba M, Tang H, He Q, Liao Q, Yang X, Guan T, Liang H, Cui S, On Behalf Of The Chinese Peritoneal Oncology Study Group. Hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis: A multicenter propensity score-matched cohort study. Chin J Cancer Res 2020;32:794-803. [PMID: 33447001 DOI: 10.21147/j.issn.1000-9604.2020.06.12] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
128 Lu J, Bang H, Kim SM, Cho SJ, Ashktorab H, Smoot DT, Zheng CH, Ryeom SW, Yoon SS, Yoon C, Lee JH. Lymphatic metastasis-related TBL1XR1 enhances stemness and metastasis in gastric cancer stem-like cells by activating ERK1/2-SOX2 signaling. Oncogene 2021;40:922-36. [PMID: 33288885 DOI: 10.1038/s41388-020-01571-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
129 Yesseyeva G, Aikemu B, Hong H, Yu C, Dong F, Sun J, Zang L, Zheng M, Ma J. Prefoldin subunits (PFDN1-6) serve as poor prognostic markers in gastric cancer. Biosci Rep 2020;40:BSR20192712. [PMID: 31957800 DOI: 10.1042/BSR20192712] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
130 Wang K, Li E, Busuttil RA, Kong JC, Pattison S, Sung JJY, Yu J, El-Omar EM, Simpson JA, Boussioutas A. A cohort study and meta-analysis of the evidence for consideration of Lauren subtype when prescribing adjuvant or palliative chemotherapy for gastric cancer. Ther Adv Med Oncol 2020;12:1758835920930359. [PMID: 32754227 DOI: 10.1177/1758835920930359] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
131 Wu P, Wang P, Ma B, Yin S, Tan Y, Hou W, Wang Z, Xu H, Zhu Z. Palliative gastrectomy plus chemotherapy versus chemotherapy alone for incurable advanced gastric cancer: a meta-analysis. Cancer Manag Res 2018;10:4759-71. [PMID: 30464590 DOI: 10.2147/CMAR.S179368] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
132 Zhang L, Wang Z, Xiao J, Zhang Z, Li H, Li F, Zhang L, Wang Y. Prognostic Value of Albumin to D-Dimer Ratio in Advanced Gastric Cancer. J Oncol 2021;2021:9973743. [PMID: 34239566 DOI: 10.1155/2021/9973743] [Reference Citation Analysis]
133 Wang Y, Zheng K, Huang Y, Xiong H, Su J, Chen R, Zou Y. PARP inhibitors in gastric cancer: beacon of hope. J Exp Clin Cancer Res 2021;40:211. [PMID: 34167572 DOI: 10.1186/s13046-021-02005-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
134 He Z, Xu JG. Evaluation of the efficiency and safety of combined chemotherapy and molecular-targeted therapy in the treatment of advanced gastric cancer: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e27557. [PMID: 34766560 DOI: 10.1097/MD.0000000000027557] [Reference Citation Analysis]
135 Choi JH, Choi YW, Kang SY, Jeong GS, Lee HW, Jeong SH, Park JS, Ahn MS, Sheen SS. Combination versus single-agent as palliative chemotherapy for gastric cancer. BMC Cancer 2020;20:167. [PMID: 32122320 DOI: 10.1186/s12885-020-6666-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
136 Guo WC, Wang F. Effect of nerve electrical stimulation for treating chemotherapy-induced nausea and vomiting in patients with advanced gastric cancer: A randomized controlled trial. Medicine (Baltimore) 2018;97:e13620. [PMID: 30572473 DOI: 10.1097/MD.0000000000013620] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
137 Pakbin B, Pishkhan Dibazar S, Allahyari S, Javadi M, Farasat A, Darzi S. Probiotic Saccharomyces cerevisiae var. boulardii supernatant inhibits survivin gene expression and induces apoptosis in human gastric cancer cells. Food Sci Nutr 2021;9:692-700. [PMID: 33598154 DOI: 10.1002/fsn3.2032] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
138 Dai W, Ye J, Zhang Z, Yang L, Ren H, Wu H, Chen J, Ma J, Zhai E, Cai S, He Y. Increased expression of heat shock factor 1 (HSF1) is associated with poor survival in gastric cancer patients. Diagn Pathol 2018;13:80. [PMID: 30326922 DOI: 10.1186/s13000-018-0755-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
139 Seesing MFJ, van der Veen A, Brenkman HJF, Stockmann HBAC, Nieuwenhuijzen GAP, Rosman C, van den Wildenberg FJH, van Berge Henegouwen MI, van Duijvendijk P, Wijnhoven BPL, Stoot JHMB, Lacle M, Ruurda JP, van Hillegersberg R; Gastroesophageal Metastasectomy Group. Resection of hepatic and pulmonary metastasis from metastatic esophageal and gastric cancer: a nationwide study. Dis Esophagus 2019;32:doz034. [PMID: 31220859 DOI: 10.1093/dote/doz034] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
140 Zheng S, Wang J, Ding N, Chen W, Chen H, Xue M, Chen F, Ni J, Wang Z, Lin Z, Jiang H, Liu X, Wang L. Prodrug polymeric micelles integrating cancer-associated fibroblasts deactivation and synergistic chemotherapy for gastric cancer. J Nanobiotechnology 2021;19:381. [PMID: 34802453 DOI: 10.1186/s12951-021-01127-5] [Reference Citation Analysis]
141 Zhao D, Klempner SJ, Chao J. Progress and challenges in HER2-positive gastroesophageal adenocarcinoma. J Hematol Oncol 2019;12:50. [PMID: 31101074 DOI: 10.1186/s13045-019-0737-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
142 Zhang Z, Liu Z, Chen Z. Comparison of Treatment Efficacy and Survival Outcomes Between Asian and Western Patients With Unresectable Gastric or Gastro-Esophageal Adenocarcinoma: A Systematic Review and Meta-Analysis. Front Oncol 2022;12:831207. [DOI: 10.3389/fonc.2022.831207] [Reference Citation Analysis]
143 He P, Ma J, Liu Y, Deng H, Dong W. Hesperetin Promotes Cisplatin-Induced Apoptosis of Gastric Cancer In Vitro and In Vivo by Upregulating PTEN Expression. Front Pharmacol 2020;11:1326. [PMID: 32973533 DOI: 10.3389/fphar.2020.01326] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
144 Dijksterhuis WPM, Verhoeven RHA, Meijer SL, Slingerland M, Haj Mohammad N, de Vos-Geelen J, Beerepoot LV, van Voorthuizen T, Creemers GJ, van Oijen MGH, van Laarhoven HWM. Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study. Gastric Cancer 2020;23:579-90. [PMID: 31927675 DOI: 10.1007/s10120-020-01039-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
145 Shen X, Gu Y, Yu S, Gong P, Mao Y, Li Y, Zheng Y, Qiao F, Zhao Z, Fan H. Silenced PITX1 promotes chemotherapeutic resistance to 5-fluorocytosine and cisplatin in gastric cancer cells. Exp Ther Med 2019;17:4046-54. [PMID: 31007741 DOI: 10.3892/etm.2019.7459] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
146 Dai ZT, Xiang Y, Zhang XY, Zong QB, Wu QF, Huang Y, Shen C, Li JP, Ponnambalam S, Liao XH. Regulation of follistatin-like 3 expression by miR-486-5p modulates gastric cancer cell proliferation, migration and tumor progression. Aging (Albany NY) 2021;13:20302-18. [PMID: 34425560 DOI: 10.18632/aging.203412] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
147 Li B, Chen L, Luo HL, Yi FM, Wei YP, Zhang WX. Docetaxel, cisplatin, and 5-fluorouracil compared with epirubicin, cisplatin, and 5-fluorouracil regimen for advanced gastric cancer: A systematic review and meta-analysis. World J Clin Cases 2019; 7(5): 600-615 [PMID: 30863759 DOI: 10.12998/wjcc.v7.i5.600] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
148 Li Y, Sui X, Su Z, Yu C, Shi X, Johnson NL, Chu F, Li Y, Li K, Ding X. Meta-Analysis of Paclitaxel-Based Chemotherapy Combined With Traditional Chinese Medicines for Gastric Cancer Treatment. Front Pharmacol 2020;11:132. [PMID: 32174834 DOI: 10.3389/fphar.2020.00132] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
149 Pietrantonio F, Morano F, Niger M, Corallo S, Antista M, Raimondi A, Prisciandaro M, Pagani F, Prinzi N, Nichetti F, Randon G, Torchio M, Corti F, Ambrosini M, Palermo F, Palazzo M, Biamonte L, Platania M, Sposito C, Cosimelli M, Mazzaferro V, Pusceddu S, Cremolini C, de Braud F, Di Bartolomeo M. Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan. Clin Colorectal Cancer 2020;19:156-64. [PMID: 32513593 DOI: 10.1016/j.clcc.2020.05.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
150 Trastulli S, Desiderio J, Lin JX, Reim D, Zheng CH, Borghi F, Cianchi F, Norero E, Nguyen NT, Qi F, Coratti A, Cesari M, Bazzocchi F, Alimoglu O, Brower ST, Pernazza G, D'Imporzano S, Azagra JS, Zhou YB, Cao SG, Garofoli E, Mosillo C, Guerra F, Liu T, Arcuri G, González P, Staderini F, Marano A, Terrenato I, D'Andrea V, Bracarda S, Huang CM, Parisi A. Laparoscopic Compared with Open D2 Gastrectomy on Perioperative and Long-Term, Stage-Stratified Oncological Outcomes for Gastric Cancer: A Propensity Score-Matched Analysis of the IMIGASTRIC Database. Cancers (Basel) 2021;13:4526. [PMID: 34572753 DOI: 10.3390/cancers13184526] [Reference Citation Analysis]
151 Tan JW, Wang L, Chen Y, Xi W, Ji J, Xu X, Zou LK, Feng JX, Zhang J, Zhang H. Predicting Chemotherapeutic Response for Far-advanced Gastric Cancer by Radiomics with Deep Learning Semi-automatic Segmentation. J Cancer. 2020;11:7224-7236. [PMID: 33193886 DOI: 10.7150/jca.46704] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
152 Li X, Yang D, Ranganathan P. Editorial: Chemo-Resistance in Gastrointestinal Cancers. Front Oncol 2022;12:821212. [DOI: 10.3389/fonc.2022.821212] [Reference Citation Analysis]
153 Fornaro L, Spallanzani A, de Vita F, D'Ugo D, Falcone A, Lorenzon L, Tirino G, Cascinu S; GAIN (GAstric Cancer Italian Network). Beyond the Guidelines: The Grey Zones of the Management of Gastric Cancer. Consensus Statements from the Gastric Cancer Italian Network (GAIN). Cancers (Basel) 2021;13:1304. [PMID: 33804024 DOI: 10.3390/cancers13061304] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
154 Zhang SX, Liu W, Ai B, Sun LL, Chen ZS, Lin LZ. Current Advances and Outlook in Gastric Cancer Chemoresistance: A Review. Recent Pat Anticancer Drug Discov 2021. [PMID: 34587888 DOI: 10.2174/1574892816666210929165729] [Reference Citation Analysis]
155 Vergadis C, Schizas D. Is Accurate N - Staging for Gastric Cancer Possible? Front Surg 2018;5:41. [PMID: 29904636 DOI: 10.3389/fsurg.2018.00041] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
156 Gershtein ES, Korotkova EA, Petrosyan AP, Suleymanov EA, Stilidi IS, Kushlinskii NE. Prognostic significance of VEGF signaling system components and matrix metalloproteinases in blood serum of gastric cancer patients. Klin Lab Diagn 2021;66:650-4. [PMID: 34882348 DOI: 10.51620/0869-2084-2021-66-11-650-654] [Reference Citation Analysis]
157 Pan S, Li K, Huang B, Huang J, Xu H, Zhu Z. Efficacy and safety of immune checkpoint inhibitors in gastric cancer: a network meta-analysis of well-designed randomized controlled trials. Ann Transl Med 2021;9:290. [PMID: 33708917 DOI: 10.21037/atm-20-6639] [Reference Citation Analysis]
158 Yu S, Hu C, Cai L, Du X, Lin F, Yu Q, Liu L, Zhang C, Liu X, Li W, Zhan Y. Seven-Gene Signature Based on Glycolysis Is Closely Related to the Prognosis and Tumor Immune Infiltration of Patients With Gastric Cancer. Front Oncol 2020;10:1778. [PMID: 33072557 DOI: 10.3389/fonc.2020.01778] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
159 Guo W, Chen Z, Li Z, Huang H, Ren Y, Zhao B, Li G, Hu Y. Improved immunotherapy for gastric cancer by nanocomposites with capability of triggering Dual-Damage of Nuclear/Mitochondrial DNA and cGAS/STING-Mediated innate immunity. Chemical Engineering Journal 2022;443:136428. [DOI: 10.1016/j.cej.2022.136428] [Reference Citation Analysis]
160 Yao K, Wei L, Zhang J, Wang C, Wang C, Qin C, Li S. Prognostic values of GPNMB identified by mining TCGA database and STAD microenvironment. Aging (Albany NY) 2020;12:16238-54. [PMID: 32833670 DOI: 10.18632/aging.103646] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
161 Huang L, Jansen L, Verhoeven RHA, Ruurda JP, Van Eycken L, De Schutter H, Johansson J, Lindblad M, Johannesen TB, Zadnik V, Žagar T, Mägi M, Lagarde SM, Bastiaannet E, van de Velde CJH, Schrotz-King P, Brenner H. Largely varying patterns and trends of primary cancer-directed resection for gastric carcinoma with synchronous distant metastasis in Europe and the US: a population-based study calling for further standardization of care. Ther Adv Med Oncol 2021;13:17588359211027837. [PMID: 34262618 DOI: 10.1177/17588359211027837] [Reference Citation Analysis]
162 Berger Y, Giurcanu M, Vining CC, Schuitevoerder D, Posner MC, Roggin KK, Polite BN, Liao CY, Eng OS, Catenacci DVT, Turaga KK. Cytoreductive Surgery for Selected Patients Whose Metastatic Gastric Cancer was Treated with Systemic Chemotherapy. Ann Surg Oncol 2021;28:4433-43. [PMID: 33420565 DOI: 10.1245/s10434-020-09475-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
163 Catenacci DVT, Moya S, Lomnicki S, Chase LM, Peterson BF, Reizine N, Alpert L, Setia N, Xiao SY, Hart J, Siddiqui UD, Hogarth DK, Eng OS, Turaga K, Roggin K, Posner MC, Chang P, Narula S, Rampurwala M, Ji Y, Karrison T, Liao CY, Polite BN, Kindler HL. Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease. Cancer Discov 2021;11:308-25. [PMID: 33234578 DOI: 10.1158/2159-8290.CD-20-1408] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
164 Chen ZX, Li J, Liu WB, Zhang SR, Sun H. Elemene-containing hyperthermic intraperitoneal chemotherapy combined with chemotherapy for elderly patients with peritoneal metastatic advanced gastric cancer. World J Clin Cases 2022; 10(5): 1498-1507 [DOI: 10.12998/wjcc.v10.i5.1498] [Reference Citation Analysis]
165 Wu K, Zhu Z, He Y, Huang L, Yan X, Wang D. Efficacy and Safety of Xiao Ai Ping Injection Combined with Chemotherapy in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis. Evid Based Complement Alternat Med 2019;2019:3821053. [PMID: 31236124 DOI: 10.1155/2019/3821053] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
166 Mu Q, Lv Y, Luo C, Liu X, Huang C, Xiu Y, Tang L. Research Progress on the Functions and Mechanism of circRNA in Cisplatin Resistance in Tumors. Front Pharmacol 2021;12:709324. [PMID: 34566636 DOI: 10.3389/fphar.2021.709324] [Reference Citation Analysis]
167 Song X, Qi W, Guo J, Sun L, Ding A, Zhao G, Li H, Qiu W, Lv J. Immune checkpoint inhibitor combination therapy for gastric cancer: Research progress. Oncol Lett 2020;20:46. [PMID: 32802168 DOI: 10.3892/ol.2020.11905] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
168 de la Fouchardiere C, Decoster L, Samalin E, Terret C, Kenis C, Droz JP, Coutzac C, Smyth E. Advanced oesophago-gastric adenocarcinoma in older patients in the era of immunotherapy. A review of the literature. Cancer Treat Rev 2021;100:102289. [PMID: 34583303 DOI: 10.1016/j.ctrv.2021.102289] [Reference Citation Analysis]
169 Tintelnot J, Goekkurt E, Binder M, Thuss-Patience P, Lorenzen S, Knorrenschild JR, Kretzschmar A, Ettrich T, Lindig U, Jacobasch L, Pink D, Al-Batran SE, Hinke A, Hegewisch-Becker S, Nilsson S, Bokemeyer C, Stein A. Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217). BMC Cancer 2020;20:503. [PMID: 32487035 DOI: 10.1186/s12885-020-06958-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
170 Yang X, Cai S, Shu Y, Deng X, Zhang Y, He N, Wan L, Chen X, Qu Y, Yu S. Exosomal miR-487a derived from m2 macrophage promotes the progression of gastric cancer. Cell Cycle 2021;20:434-44. [PMID: 33522393 DOI: 10.1080/15384101.2021.1878326] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
171 Kundel Y, Sternschuss M, Moore A, Perl G, Brenner B, Goldvaser H. Efficacy of immune-checkpoint inhibitors in metastatic gastric or gastroesophageal junction adenocarcinoma by patient subgroups: A systematic review and meta-analysis. Cancer Med 2020;9:7613-25. [PMID: 32869544 DOI: 10.1002/cam4.3417] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
172 Tsuji T, Maeda Y, Kita K, Murakami K, Saya H, Takemura H, Inaki N, Oshima M, Oshima H. FOXO3 is a latent tumor suppressor for FOXO3-positive and cytoplasmic-type gastric cancer cells. Oncogene 2021;40:3072-86. [PMID: 33795838 DOI: 10.1038/s41388-021-01757-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
173 Catenacci DVT, Rasco D, Lee J, Rha SY, Lee KW, Bang YJ, Bendell J, Enzinger P, Marina N, Xiang H, Deng W, Powers J, Wainberg ZA. Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma. J Clin Oncol 2020;38:2418-26. [PMID: 32167861 DOI: 10.1200/JCO.19.01834] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
174 Ye Z, Chen J, Rao Y, Yang W. Should S-1 be better than capecitabine for patients with advanced gastric cancer in Asia? A systematic review and meta-analysis. Onco Targets Ther 2019;12:269-77. [PMID: 30643425 DOI: 10.2147/OTT.S187815] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
175 Reid JL, Kanhere HA, Hewett PJ, Price TJ, Maddern GJ, Trochsler MI. Can pressurised intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC-O+) be added to standard treatment for resectable high-risk gastric cancer patients? A study protocol. Pleura and Peritoneum 2021;6:151-4. [DOI: 10.1515/pp-2021-0132] [Reference Citation Analysis]
176 Wu CE, Xue WW, Zhuang YW, Ding DW, Zhou JY, Liu SL, Wang RP, Shu P. A clinical study on the efficacy of Yiqi Huayu Jiedu decoction for reducing the risk of postoperative recurrence and metastasis of gastric cancer: Protocol for a multicenter, randomized, double-blind, placebo-controlled trial. Medicine (Baltimore) 2020;99:e23417. [PMID: 33235121 DOI: 10.1097/MD.0000000000023417] [Reference Citation Analysis]
177 Ge J, Liu T, Lei T, Li X, Song K, Azizi S, Liu H, Tang M. Retrospective Cohort Study of Intraoperative Administration of Sustained-Release 5-Fluorouracil Implants in Advanced Gastric Cancer Patients. Front Pharmacol 2021;12:659258. [PMID: 33927633 DOI: 10.3389/fphar.2021.659258] [Reference Citation Analysis]
178 Zhou PZ, Gao L, Wu W, Hao YX. Clinical effects of Apatinib combined with DOS neoadjuvant chemotherapy regimen in neoadjuvant chemotherapy for LAGC. Pak J Med Sci 2021;37:1890-5. [PMID: 34912413 DOI: 10.12669/pjms.37.7.4265] [Reference Citation Analysis]
179 Kou Y, Tong B, Wu W, Liao X, Zhao M. Berberine Improves Chemo-Sensitivity to Cisplatin by Enhancing Cell Apoptosis and Repressing PI3K/AKT/mTOR Signaling Pathway in Gastric Cancer. Front Pharmacol 2020;11:616251. [PMID: 33362566 DOI: 10.3389/fphar.2020.616251] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
180 Cheng H, Sun A, Guo Q, Zhang Y. Efficacy and safety of apatinib combined with chemotherapy for the treatment of advanced gastric cancer in the Chinese population: a systematic review and meta-analysis. Drug Des Devel Ther 2018;12:2173-83. [PMID: 30034222 DOI: 10.2147/DDDT.S170678] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
181 Chan WL, Lam KO, So TH, Lee VH, Kwong LD. Third-line systemic treatment in advanced/metastatic gastric cancer: a comprehensive review. Ther Adv Med Oncol 2019;11:1758835919859990. [PMID: 31285759 DOI: 10.1177/1758835919859990] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
182 Dijksterhuis WPM, Verhoeven RHA, Slingerland M, Haj Mohammad N, de Vos-Geelen J, Beerepoot LV, van Voorthuizen T, Creemers GJ, van Oijen MGH, van Laarhoven HWM. Heterogeneity of first-line palliative systemic treatment in synchronous metastatic esophagogastric cancer patients: A real-world evidence study. Int J Cancer. 2020;146:1889-1901. [PMID: 31340065 DOI: 10.1002/ijc.32580] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
183 Tjulandin SA, Tryakin AA, Besova NS, Sholokhova E, Ivanova JI, Cheng WY, Schmerold LM, Thompson-Leduc P, Novick D. Real-world treatment patterns among patients with advanced gastric cancer in Russia: a chart review study. J Drug Assess 2019;8:150-8. [PMID: 31656688 DOI: 10.1080/21556660.2019.1669610] [Reference Citation Analysis]
184 Dalhammar K, Malmström M, Sandberg M, Falkenback D, Kristensson J. Health care utilization among patients with oesophageal and gastric cancer: the impact of initial treatment strategy and assignment of a contact nurse. BMC Health Serv Res 2021;21:1019. [PMID: 34579714 DOI: 10.1186/s12913-021-07042-7] [Reference Citation Analysis]
185 He Z, Tian S, Gao Y, Meng F, Luo L. Luminescent AIE Dots for Anticancer Photodynamic Therapy. Front Chem 2021;9:672917. [PMID: 34113602 DOI: 10.3389/fchem.2021.672917] [Reference Citation Analysis]
186 Di Bartolomeo M, Niger M, Morano F, Corallo S, Antista M, Tamberi S, Lonardi S, Di Donato S, Berardi R, Scartozzi M, Cardellino GG, Di Costanzo F, Rimassa L, Luporini AG, Longarini R, Zaniboni A, Bertolini A, Tomasello G, Pinotti G, Scagliotti G, Tortora G, Bonetti A, Spallanzani A, Frassineti GL, Tassinari D, Giuliani F, Cinieri S, Maiello E, Verusio C, Bracarda S, Catalano V, Basso M, Ciuffreda L, De Vita F, Parra HS, Fornaro L, Caporale M, de Braud F, Pietrantonio F. Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial. BMC Cancer 2019;19:283. [PMID: 30922323 DOI: 10.1186/s12885-019-5498-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
187 Ooki A, Yamaguchi K. The beginning of the era of precision medicine for gastric cancer with fibroblast growth factor receptor 2 aberration. Gastric Cancer 2021. [PMID: 34398359 DOI: 10.1007/s10120-021-01235-z] [Reference Citation Analysis]
188 Zha Z, Zhang P, Li D, Liu G, Lu L. Identification and Construction of a Long Noncoding RNA Prognostic Risk Model for Stomach Adenocarcinoma Patients. Dis Markers 2021;2021:8895723. [PMID: 33680217 DOI: 10.1155/2021/8895723] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
189 Duan S, Wang P, Liu F, Huang H, An W, Pan S, Wang X. Novel immune-risk score of gastric cancer: A molecular prediction model combining the value of immune-risk status and chemosensitivity. Cancer Med 2019;8:2675-85. [PMID: 30945466 DOI: 10.1002/cam4.2077] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
190 Fong CY, Chau I. Harnessing biomarkers of response to improve therapy selection in esophago-gastric adenocarcinoma. Pharmacogenomics 2021;22:703-26. [PMID: 34120461 DOI: 10.2217/pgs-2020-0090] [Reference Citation Analysis]
191 Salehi Kahish R, Alghasi A, Hadadi S, Abasi Nasab M, Mafakherzadeh A. The Prevalence of Blastocystis Infection in Pediatric Patients with Malignancy: A Single-Center Study in Ahvaz, Iran. Arch Pediatr Infect Dis 2021;9. [DOI: 10.5812/pedinfect.104068] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
192 Roviello G, D'Angelo A, Roudi R, Petrioli R, Mini E. Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights. J Oncol 2019;2019:5692317. [PMID: 31354820 DOI: 10.1155/2019/5692317] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
193 Yin HM, He Q, Chen J, Li Z, Yang W, Hu X. Drug metabolism-related eight-gene signature can predict the prognosis of gastric adenocarcinoma. J Clin Lab Anal 2021;35:e24085. [PMID: 34773716 DOI: 10.1002/jcla.24085] [Reference Citation Analysis]
194 Zhao Y, He J, Li Y, Xu M, Peng X, Mao J, Xu B, Cui H. PHF14 Promotes Cell Proliferation and Migration through the AKT and ERK1/2 Pathways in Gastric Cancer Cells. Biomed Res Int 2020;2020:6507510. [PMID: 32596345 DOI: 10.1155/2020/6507510] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
195 Wang H, Chen B, Lin Y, Zhou Y, Li X. Legumain Promotes Gastric Cancer Progression Through Tumor-associated Macrophages In vitro and In vivo. Int J Biol Sci 2020;16:172-80. [PMID: 31892854 DOI: 10.7150/ijbs.36467] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
196 Li M, Wang X, Liu J, Mao X, Li D, Wang Z, Tang Y, Wu S. Identification of Core Prognosis-Related Candidate Genes in Chinese Gastric Cancer Population Based on Integrated Bioinformatics. Biomed Res Int 2020;2020:8859826. [PMID: 33381592 DOI: 10.1155/2020/8859826] [Reference Citation Analysis]
197 Wang S, Chen W, Yu H, Song Z, Li Q, Shen X, Wu Y, Zhu L, Ma Q, Xing D. lncRNA ROR Promotes Gastric Cancer Drug Resistance. Cancer Control 2020;27:1073274820904694. [PMID: 32019330 DOI: 10.1177/1073274820904694] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
198 Oh SJ. Long-Term Survival of Two Patients with Liver Metastases from Advanced Gastric Cancer Treated with Radiofrequency Ablation and Chemotherapy. Case Rep Oncol 2021;14:67-72. [PMID: 33776684 DOI: 10.1159/000507849] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
199 Merz V, Zecchetto C, Simionato F, Cavaliere A, Casalino S, Pavarana M, Giacopuzzi S, Bencivenga M, Tomezzoli A, Santoro R, Fedele V, Contarelli S, Rossi I, Giacomazzi S, Pasquato M, Piazzola C, Milleri S, de Manzoni G, Melisi D. A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal-gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial. Ther Adv Med Oncol 2020;12:1758835920937889. [PMID: 32684989 DOI: 10.1177/1758835920937889] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
200 Ngai LL, Ter Veer E, van den Boorn HG, van Herk EH, van Kleef JJ, van Oijen MGH, van Laarhoven HWM. TOXview: a novel graphical presentation of cancer treatment toxicity profiles. Acta Oncol 2019;58:1138-48. [PMID: 31017020 DOI: 10.1080/0284186X.2019.1601256] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
201 Zhuang J, Liu X, Yang Y, Zhang Y, Guan G. Sulfasalazine, a potent suppressor of gastric cancer proliferation and metastasis by inhibition of xCT: Conventional drug in new use. J Cell Mol Med 2021;25:5372-80. [PMID: 33988296 DOI: 10.1111/jcmm.16548] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
202 Miao X, Liu Y, Fan Y, Wang G, Zhu H. LncRNA BANCR Attenuates the Killing Capacity of Cisplatin on Gastric Cancer Cell Through the ERK1/2 Pathway. Cancer Manag Res 2021;13:287-96. [PMID: 33469371 DOI: 10.2147/CMAR.S269679] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]